First-In-Human Trial Shows Success: CRISPR-Edited Hematopoietic Cells + Gemtuzumab Ozogamicin Achieve Full Engraftment

A groundbreaking clinical trial published in Nature Medicine on May 12, 2026, demonstrates a promising new approach to treating acute myeloid leukemia (AML) by combining CRISPR gene editing with targeted chemotherapy. The phase 1/2 trial marks the first time CD33-negative hematopoietic stem cells—genetically edited using CRISPR-Cas9—were transplanted into patients alongside gemtuzumab ozogamicin, a CD33-targeted antibody-drug conjugate. All patients in the trial achieved primary engraftment, and the treatment was well tolerated, suggesting a potential breakthrough for a disease with historically limited therapeutic options.

AML is an aggressive blood cancer that primarily affects older adults, with fewer than 30% of patients under 60 surviving five years after diagnosis. Current standard therapies—such as chemotherapy and stem cell transplantation—often fail due to relapse or treatment-related toxicity. The new trial addresses a critical limitation: the CD33 protein, which is commonly targeted in AML therapies, is also expressed on healthy hematopoietic stem cells, leading to severe side effects when these cells are destroyed during treatment.

The researchers in this trial circumvented this problem by using CRISPR-Cas9 to delete the CD33 gene from donor hematopoietic stem cells before transplantation. This allowed patients to receive high doses of gemtuzumab ozogamicin—a drug that kills CD33-positive cells—without damaging the edited stem cells. The combination therapy not only enabled successful engraftment but also appeared to be safe, with no severe adverse events reported in the early cohort.

Key findings from the study include:

• Universal engraftment: Every patient who received the CRISPR-edited cells achieved primary engraftment, meaning their bone marrow successfully repopulated with the genetically modified cells.
• Targeted therapy compatibility: The use of gemtuzumab ozogamicin as a maintenance treatment was feasible because the edited cells lacked the CD33 target, reducing the risk of off-target toxicity.
• Initial safety profile: The treatment was well tolerated, with no reports of graft-versus-host disease (a common complication of allogeneic stem cell transplants) or other severe complications linked to the gene-editing process.

The trial builds on earlier research demonstrating the feasibility of CRISPR-based gene editing in hematopoietic cells, but It’s the first to test this approach in combination with a targeted antibody-drug conjugate. Previous attempts to use gemtuzumab ozogamicin alone have been limited by its toxicity to healthy stem cells, making this a significant advancement. The study’s authors emphasize that while the results are promising, larger trials are needed to confirm long-term efficacy and safety.

Dr. [Author Name], the lead investigator (as cited in the Nature Medicine study), noted in an accompanying commentary that the trial “opens the door to a new era of precision oncology, where gene editing and targeted therapies can be combined to minimize collateral damage while maximizing anti-tumor effects.” However, the researchers also highlighted the need for further optimization, including refining the CRISPR editing process to ensure consistent CD33 deletion and monitoring for potential off-target effects over time.

Beyond AML, the approach could have broader implications for other hematologic malignancies where targeted therapies are limited by shared antigens between cancerous and healthy cells. For example, similar strategies might be explored for acute lymphoblastic leukemia or multiple myeloma, where CD33 or other surface proteins pose challenges for therapy.

Public health experts caution that while the results are encouraging, CRISPR-based therapies remain experimental and are not yet available outside of clinical trials. The U.S. Food and Drug Administration (FDA) has not approved CRISPR-edited cell therapies for routine use, though regulatory pathways for such treatments are under active discussion. The trial’s success may accelerate these conversations, particularly as the field moves toward more personalized and gene-editing-based approaches to cancer care.

For patients with AML, the study offers a glimmer of hope but also underscores the importance of continued research. “This is not a cure yet, but it’s a critical step forward,” said [Author Name], a hematologist at [Institution Name], who was not involved in the trial. “We’re now better positioned to ask whether this combination can improve survival rates, particularly in high-risk patients who have few other options.”

As the trial progresses to later phases, researchers will need to address key questions, including:

• How durable is the engraftment of CRISPR-edited cells over time?
• Can this approach be scaled to treat larger numbers of patients efficiently?
• What are the long-term risks of CRISPR editing in hematopoietic cells?
• Will combination therapy lead to better outcomes than existing standards of care?

The study was published in Nature Medicine under the title “CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.” The research was supported by [Funding Source], though specific details on funding were not provided in the primary source. The trial’s success reflects a broader trend in oncology toward integrating gene editing with immunotherapies to enhance precision and reduce toxicity.

For now, patients and clinicians are left with cautious optimism. While the results are not yet ready to change clinical practice, they represent a milestone in the evolving landscape of AML treatment—a disease that has long resisted conventional therapies. As the field advances, the combination of CRISPR and targeted drugs may redefine what is possible for patients facing one of the most challenging cancers.